3-Hydroxytyramine hydrochloride cas: 62-31-7

CAS NO: 62-31-7
3-Hydroxytyramine hydrochloride
Description Review
Description

3-Hydroxytyramine hydrochloride, also known as dopamine hydrochloride, is a neurotransmitter and medication used in the treatment of several medical conditions. It is an organic compound with the chemical name (2S)-3-(3,4-dihydroxyphenyl)-2-hydroxypropylamine hydrochloride and molecular formula C8H12ClNO2. The formula weight of 3-Hydroxytyramine hydrochloride is 189.64 g/mol and its CAS number is 62-31-7.

Top Ten Keywords and Synonyms

  1. 3-Hydroxytyramine uses
  2. Dopamine hydrochloride mechanism of action
  3. Dopamine deficiency
  4. Parkinson's disease treatment
  5. Schizophrenia treatment
  6. Depression treatment
  7. Attention deficit hyperactivity disorder (ADHD) treatment
  8. Substance abuse treatment
  9. Dopamine agonist
  10. Dopamine metabolism

Health Benefits of 3-Hydroxytyramine Hydrochloride 3-Hydroxytyramine hydrochloride is primarily used to treat several medical conditions such as Parkinson's disease, depression, schizophrenia, attention deficit hyperactivity disorder, and substance abuse. As a neurotransmitter, it plays an essential role in regulating mood, motivation, reward, and movement.

Potential Effects of 3-Hydroxytyramine Hydrochloride 3-Hydroxytyramine hydrochloride has been shown to effectively treat Parkinson's disease symptoms by restoring dopamine levels in the brain. It may also improve symptoms of depression and schizophrenia by increasing dopamine activity in specific brain regions. Additionally, research suggests that dopamine plays a role in addiction, and 3-Hydroxytyramine hydrochloride may have potential benefits in the treatment of substance abuse disorders.

Product Mechanism 3-Hydroxytyramine hydrochloride works by acting as a dopamine receptor agonist. It binds to dopamine receptors in the brain and mimics the effects of dopamine, leading to increased dopamine activity and improved symptoms of several medical conditions. It also inhibits the reuptake of dopamine into presynaptic neurons, thereby increasing the concentration of dopamine in the synaptic cleft and enhancing neurotransmission.

Safety 3-Hydroxytyramine hydrochloride is generally considered safe when used as directed, but it may cause side effects in some individuals. Patients with a history of allergy to the medication or any of its components should not use 3-Hydroxytyramine hydrochloride. Pregnant and breastfeeding women should consult their doctor before taking this medication.

Side Effects Common side effects of 3-Hydroxytyramine hydrochloride include headache, dizziness, nausea, and vomiting. Rare but serious side effects may include irregular heartbeat, high blood pressure, and hallucinations. Patients experiencing any adverse reactions while taking 3-Hydroxytyramine hydrochloride should seek medical attention immediately.

Dosing Information The recommended dosage of 3-Hydroxytyramine hydrochloride varies depending on the condition being treated and the patient's individual needs. It is typically taken orally in the form of tablets or capsules, often two to three times per day. Dosing should be carefully monitored by a healthcare provider, and any changes to the regimen should be made under their guidance.

Conclusion 3-Hydroxytyramine hydrochloride is a neurotransmitter and medication primarily used to treat several medical conditions such as Parkinson's disease, depression, schizophrenia, attention deficit hyperactivity disorder, and substance abuse. It works by acting as a dopamine receptor agonist and inhibiting the reuptake of dopamine into presynaptic neurons. While generally considered safe, 3-Hydroxytyramine hydrochloride may cause side effects such as headache, nausea, and vomiting, and should not be used in patients with a history of allergy to the medication. Careful dosing and monitoring by a healthcare provider is essential for safe and effective use of 3-Hydroxytyramine hydrochloride. Its potential benefits in the treatment of other medical conditions warrant further investigation.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code